- Drugs
- Friday, 09 Jun 2023
Brazil Vitamin K2 Market is expected to reach US$ 9.81 million by 2028
MK-7 Segment to Dominate Brazil Vitamin K2 Market During 2023–2028
According to our new research study on "Brazil Vitamin K2 Market Forecast to 2028 – COVID-19 Impact and Country Analysis – by Product, Dosage Forms, Source and Application," the market is expected to grow from US$ 1.59 million in 2022 to US$ 9.81 million by 2028; it is estimated to register a CAGR of 35.6% from 2023 to 2028. Key factors driving the Brazil Vitamin K2 market growth are increasing prevalence of CVD and growing cases of osteoporosis bone deformation in adults and newborns. However, lack of awareness might hamper the growth.
MK-7 is the leading segment by product of the Brazil vitamin K2 market. And the same segment is estimated to hold the maximum Brazil vitamin K2 market share during the forecast period. The segment is also anticipated to grow at the fastest CAGR during the forecast period. Menaquinone-7 (MK-7) is an advanced, fat-soluble form of vitamin K2 that serves multiple bodily functions. Only vitamin K2 in the form of MK-7 has been proven to provide 24-hour protection to bones and teeth from a single daily dose. MK-7 has a much longer half-life in the body and stays in the blood the longest than other forms of vitamin K2 owing to its presence not only in liver tissues but also in bones, arteries, and soft tissues. Therefore, MK-7 supplementation must only be taken once daily. According to MenaQ7, 45 mcg of MK-7 per day can increase carboxylation and activate vitamin K-dependent proteins, such as osteocalcin for bone health and Matrix GLA Protein (MGP) for heart health.
Brazil Vitamin K2 Market, by Product, 2022 (%)
Source: The Insight Partners Analysis
Various companies in the market offer MK-7 in different forms, such as soft gel capsules, gummies, and oil. MK-7 is used for broader applications, including human health, skincare, and many more.
The other segment by product is MK-4. It, also known as menatetrenone (INN), is one of the nine forms of vitamin K2 with low bioactivity and bioavailability. In most cases, synthetic MK-4 is used for pharmacological purposes. Studies show that vitamin K2 supplements can heal fractures and improve bone quality in osteoporosis patients. The commercially available MK-4 stays only for 4–6 hours in the body and is effective at significantly higher dosages. MK-4 stops and reverses bone loss, thereby strengthening bones and reducing the chances of fractures by over 80%.
Lesaffre (Natto Pharma); DSM (DSM-Firmenich); PLT Health Solutions Inc; International Flavors & Fragrances Inc; BASF SE; AdvaCare Pharma USA LLC; Metabolics Ltd; IAF Network SpA (Yamamoto Nutrition); Balchem Corp, and Biolab Sanus Farmaceutica Ltd. among others are among the key companies operating in the Brazil vitamin K2 market.
The report segments the Brazil Vitamin K2 Market as follows:
Based on product, the Brazil vitamin K2 market is segmented into MK-4, MK-7, and combination drugs. In 2022, the MK-7 segment held the largest share of the market. Moreover, the same segment is estimated to grow at a significant CAGR during the forecast period. Based on dosage forms, the market is segmented into capsules and tablets, powder, and oils. In 2022, the powder segment held the larger share of the market. Moreover, the same segment is estimated to grow at a significant CAGR during the forecast period. Based on the source, the Brazil vitamin K2 market is classified into natural and synthetic. In 2022, the natural segment held the largest market share. Further, the same segment is expected to grow at the fastest CAGR during the coming years. And based on the application, the Brazil vitamin K2 market is segmented into pharmaceuticals, nutraceuticals and food, and others. In 2022, the pharmaceuticals segment held the largest market share. However, the nutraceuticals and food segment are estimated to grow at a significant CAGR during the forecast period.
Contact Us
Contact Us: The Insight Partners
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com
Related Industry Updates
Anti-Viral Therapies Market is expected to reach US$ 82,928.76 million in 2028
Jan 16, 2023
Advancements in Healthcare industry is driving More R & D for Subcutaneous Drug Delivery
Oct 04, 2019
Investors Hunting for Winners in Ashes of Industry Fire up Rally in Cannabis Stocks
Jan 24, 2020
Glioma Treatment Market is expected to reach US$ 8,291.3 million by 2030
Sep 18, 2023
Ionis Pharmaceuticals to present at upcoming virtual investor conferences
Jun 05, 2020
CaaMTech Collaborates With National Institutes of Health to Research Psychedelics
May 08, 2020
Is Hydroxychloroquine Really a Game Changer in the fight against COVID-19?
Apr 15, 2020